Wells Fargo analyst Mohit Bansal lowered the firm’s price target on BioNTech (BNTX) to $150 from $170 to reflect Bristol Myers (BMY), while keeping an Overweight rating on the shares. The firm notes several oncology updates are expected this year, including BNT327 dose optimization data gating Phase 3 starts and first adjuvant setting readout for the personalized cancer vaccine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Strategic Oncology Focus and Strong Financials Drive Buy Rating
- BioNTech’s Strategic Moves and Financial Outlook
- BioNTech price target raised to $134 from $126 at BofA
- BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation
- Cautious Hold on BioNTech SE Amid Revenue Uncertainty and Competitive Challenges